IRIS Accounts Production v24.3.2.46 SC029195 Board of Directors Board of Directors 1.7.23 30.6.24 30.6.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC0291952023-06-30SC0291952024-06-30SC0291952023-07-012024-06-30SC0291952022-06-30SC0291952022-07-012023-06-30SC0291952023-06-30SC029195ns15:Scotland2023-07-012024-06-30SC029195ns14:PoundSterling2023-07-012024-06-30SC029195ns10:Director12023-07-012024-06-30SC029195ns10:Director22023-07-012024-06-30SC029195ns10:PrivateLimitedCompanyLtd2023-07-012024-06-30SC029195ns10:SmallEntities2023-07-012024-06-30SC029195ns10:AuditExemptWithAccountantsReport2023-07-012024-06-30SC029195ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-30SC029195ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-30SC029195ns10:FullAccounts2023-07-012024-06-30SC02919512023-07-012024-06-30SC029195ns10:Director32023-07-012024-06-30SC029195ns10:Director42023-07-012024-06-30SC029195ns10:Director52023-07-012024-06-30SC029195ns10:RegisteredOffice2023-07-012024-06-30SC029195ns5:CurrentFinancialInstruments2024-06-30SC029195ns5:CurrentFinancialInstruments2023-06-30SC029195ns5:ShareCapital2024-06-30SC029195ns5:ShareCapital2023-06-30SC029195ns5:RetainedEarningsAccumulatedLosses2024-06-30SC029195ns5:RetainedEarningsAccumulatedLosses2023-06-30SC029195ns5:NetGoodwill2023-07-012024-06-30SC029195ns5:IntangibleAssetsOtherThanGoodwill2023-07-012024-06-30SC029195ns5:NetGoodwill2023-06-30SC029195ns5:NetGoodwill2024-06-30SC029195ns5:NetGoodwill2023-06-30SC029195ns5:LandBuildings2023-06-30SC029195ns5:PlantMachinery2023-06-30SC029195ns5:FurnitureFittings2023-06-30SC029195ns5:MotorVehicles2023-06-30SC029195ns5:LandBuildings2023-07-012024-06-30SC029195ns5:PlantMachinery2023-07-012024-06-30SC029195ns5:FurnitureFittings2023-07-012024-06-30SC029195ns5:MotorVehicles2023-07-012024-06-30SC029195ns5:LandBuildings2024-06-30SC029195ns5:PlantMachinery2024-06-30SC029195ns5:FurnitureFittings2024-06-30SC029195ns5:MotorVehicles2024-06-30SC029195ns5:LandBuildings2023-06-30SC029195ns5:PlantMachinery2023-06-30SC029195ns5:FurnitureFittings2023-06-30SC029195ns5:MotorVehicles2023-06-30SC029195ns5:CostValuation2024-06-30SC029195ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-30SC029195ns5:WithinOneYearns5:CurrentFinancialInstruments2023-06-30
REGISTERED NUMBER: SC029195 (Scotland)















Unaudited Financial Statements for the Year Ended 30 June 2024

for

Colinton Pharmacy Limited

Colinton Pharmacy Limited (Registered number: SC029195)






Contents of the Financial Statements
for the Year Ended 30 June 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Chartered Accountant's Report 8

Colinton Pharmacy Limited

Company Information
for the Year Ended 30 June 2024







DIRECTORS: W M Goodburn
R M Goodburn
Ms J K Goodburn
Mrs E A L Goodburn
Mrs J M Paton





REGISTERED OFFICE: Unit 6 School Brae
Peebles
EH45 8AT





REGISTERED NUMBER: SC029195 (Scotland)





ACCOUNTANT: Gall Robertson CA
Tweedside Park
Tweedbank
Galashiels
Selkirkshire
TD1 3TE

Colinton Pharmacy Limited (Registered number: SC029195)

Balance Sheet
30 June 2024

30.6.24 30.6.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 205,754 216,432
Investments 6 1,124,661 1,124,661
1,330,415 1,341,093

CURRENT ASSETS
Stocks 60,444 63,203
Debtors 7 167,309 168,942
Cash at bank and in hand 300,428 225,461
528,181 457,606
CREDITORS
Amounts falling due within one year 8 303,695 291,197
NET CURRENT ASSETS 224,486 166,409
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,554,901

1,507,502

PROVISIONS FOR LIABILITIES 11,153 17,115
NET ASSETS 1,543,748 1,490,387

CAPITAL AND RESERVES
Called up share capital 6,481 6,481
Retained earnings 1,537,267 1,483,906
1,543,748 1,490,387

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Colinton Pharmacy Limited (Registered number: SC029195)

Balance Sheet - continued
30 June 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 25 January 2025 and were signed on its behalf by:




Ms J K Goodburn - Director



R M Goodburn - Director


Colinton Pharmacy Limited (Registered number: SC029195)

Notes to the Financial Statements
for the Year Ended 30 June 2024

1. STATUTORY INFORMATION

Colinton Pharmacy Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern
The directors have assessed a period of 12 months from the date of approval of the financial statements and consider that no material uncertainties exist that cast significant doubt about the ability of the company to continue as a going concern. Thus the directors adopt the going concern basis of accounting in preparing the financial statements.

Revenue
Revenue is measured at the fair value of the consideration received or receivable from (goods supplied and services rendered), net of discounts and Value Added Tax.
Revenue from the above streams is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Goodwill
Goodwill of £3700, being the amount paid in connection with the acquisition of a business, has been written down to nil.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Colinton Pharmacy Limited (Registered number: SC029195)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Investments in associates
Investments in associate undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets, which include debtors, cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities including trade creditors and loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Colinton Pharmacy Limited (Registered number: SC029195)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

2. ACCOUNTING POLICIES - continued

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.

Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 19 (2023 - 17 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 July 2023
and 30 June 2024 3,700
AMORTISATION
At 1 July 2023
and 30 June 2024 3,700
NET BOOK VALUE
At 30 June 2024 -
At 30 June 2023 -

Colinton Pharmacy Limited (Registered number: SC029195)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

5. TANGIBLE FIXED ASSETS
Fixtures
Freehold Plant and and Motor
property machinery fittings vehicles Totals
£    £    £    £    £   
COST
At 1 July 2023 160,216 33,573 63,688 27,495 284,972
Additions - 3,157 - - 3,157
Disposals - (10,785 ) - - (10,785 )
At 30 June 2024 160,216 25,945 63,688 27,495 277,344
DEPRECIATION
At 1 July 2023 - 27,660 35,381 5,499 68,540
Charge for year - 4,562 3,774 5,499 13,835
Eliminated on disposal - (10,785 ) - - (10,785 )
At 30 June 2024 - 21,437 39,155 10,998 71,590
NET BOOK VALUE
At 30 June 2024 160,216 4,508 24,533 16,497 205,754
At 30 June 2023 160,216 5,913 28,307 21,996 216,432

6. FIXED ASSET INVESTMENTS
Interest
in
associate
£   
COST
At 1 July 2023
and 30 June 2024 1,124,661
NET BOOK VALUE
At 30 June 2024 1,124,661
At 30 June 2023 1,124,661

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.24 30.6.23
£    £   
Trade debtors 124,809 141,853
Other debtors 42,500 27,089
167,309 168,942

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.24 30.6.23
£    £   
Trade creditors 209,663 234,815
Taxation and social security 27,925 13,106
Other creditors 66,107 43,276
303,695 291,197

Chartered Accountant's Report to the Board of Directors
on the Unaudited Financial Statements of
Colinton Pharmacy Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, I have prepared for your approval the financial statements of Colinton Pharmacy Limited for the year ended 30 June 2024 which comprise the Income Statement, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given me.

As a practising member of ICAS, I am subject to its ethical and other professional requirements which are detailed at http://www.icas.com/accountspreparationguidance.

This report is made solely to the Board of Directors of Colinton Pharmacy Limited, as a body, in accordance with my terms of engagement. My work has been undertaken solely to prepare for your approval the financial statements of Colinton Pharmacy Limited and state those matters that I have agreed to state to the Board of Directors of Colinton Pharmacy Limited, as a body, in this report in accordance with the requirements of ICAS as detailed at http://www.icas.com/accountspreparationguidance. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the company and its Board of Directors, as a body, for my work or for this report.

It is your duty to ensure that Colinton Pharmacy Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Colinton Pharmacy Limited. You consider that Colinton Pharmacy Limited is exempt from the statutory audit requirement for the year.

I have not been instructed to carry out an audit or a review of the financial statements of Colinton Pharmacy Limited. For this reason, I have not verified the accuracy or completeness of the accounting records or information and explanations you have given to me and I do not, therefore, express any opinion on the statutory financial statements.






Gall Robertson CA
Tweedside Park
Tweedbank
Galashiels
Selkirkshire
TD1 3TE


31 January 2025